Antagonism of Sorafenib and Regorafenib actions by platelet factors in hepatocellular carcinoma cell lines

BACKGROUND: Platelets are frequently altered in hepatocellular carcinoma (HCC) patients. Platelet lysates (hPL) can enhance HCC cell growth and decrease apoptosis. The aims were to evaluate whether hPL can modulate the actions of Sorafenib or Regorafenib, two clinical HCC multikinase antagonists. ME...

Full beskrivning

Sparad:
Bibliografiska uppgifter
Huvudupphovsmän: D’Alessandro, Rosalba, Refolo, Maria G, Lippolis, Catia, Giannuzzi, Grazia, Carella, Nicola, Messa, Caterina, Cavallini, Aldo, Carr, Brian I
Materialtyp: Artigo
Språk:Inglês
Publicerad: BioMed Central 2014
Ämnen:
Research Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC4038078/
https://ncbi.nlm.nih.gov/pubmed/24885890
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2407-14-351
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk